ASX
Chimeric Therapeutics
CHM:ASX•Healthcare
Sensitive ASX Announcement
Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
Published: 05/06/24, 09:11am (AEST)•3 pages